LBMC Investment Advisors’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$263K Sell
10,922
-3,000
-22% -$78.5K 0.01% 216
2026
Q1
$391K Hold
13,922
0.02% 170
2025
Q4
$347K Sell
13,922
-283
-2% -$7.14K 0.02% 172
2025
Q3
$362K Sell
14,205
-836
-6% -$20.6K 0.02% 176
2025
Q2
$365K Hold
15,041
0.03% 153
2025
Q1
$381K Buy
15,041
+283
+2% +$7.41K 0.03% 136
2024
Q4
$392K Buy
14,758
+900
+6% +$24.4K 0.03% 132
2024
Q3
$401K Hold
13,858
0.03% 127
2024
Q2
$388K Sell
13,858
-1,495
-10% -$41.2K 0.03% 118
2024
Q1
$426K Sell
15,353
-1,304
-8% -$36.2K 0.04% 114
2023
Q4
$480K Sell
16,657
-236
-1% -$7.13K 0.05% 95
2023
Q3
$573K Sell
16,893
-5
-0% -$177 0.06% 90
2023
Q2
$620K Sell
16,898
-129
-0.8% -$5.02K 0.06% 85
2023
Q1
$695K Buy
17,027
+8,797
+107% +$380K 0.07% 73
2022
Q4
$422K Sell
8,230
-723
-8% -$34.7K 0.04% 104
2022
Q3
$392K Hold
8,953
0.05% 101
2022
Q2
$469K Buy
8,953
+1,000
+13% +$51K 0.05% 83
2022
Q1
$412K Sell
7,953
-58
-0.7% -$3.01K 0.04% 102
2021
Q4
$473K Buy
8,011
+5,878
+276% +$291K 0.04% 97
2021
Q3
$344K Sell
2,133
-5,858
-73% -$260K 0.03% 114
2021
Q2
$313K Buy
+7,991
New +$311K 0.03% 124
2021
Q1
Sell
-5,848
Closed -$215K 139
2020
Q4
$215K Buy
+5,848
New +$215K 0.03% 127
2020
Q2
Sell
-6,526
Closed -$202K 106
2020
Q1
$202K Hold
6,526
0.04% 86
2019
Q4
$243K Buy
6,526
+123
+2% +$4.38K 0.03% 86
2019
Q3
$218K Sell
6,403
-1,007
-14% -$36.6K 0.03% 86
2019
Q2
$305K Buy
7,410
+659
+10% +$26.2K 0.05% 74
2019
Q1
$272K Sell
6,751
-1,600
-19% -$64.1K 0.04% 78
2018
Q4
$346K Sell
8,351
-619
-7% -$25.7K 0.06% 62
2018
Q3
$375K Sell
8,970
-426
-5% -$16.4K 0.06% 71
2018
Q2
$323K Buy
9,396
+777
+9% +$26.6K 0.05% 77
2018
Q1
$290K Sell
8,619
-668
-7% -$23K 0.05% 69
2017
Q4
$319K Buy
+9,287
New +$317K 0.05% 68
2017
Q2
Sell
-6,396
Closed -$208K 76
2017
Q1
$208K Buy
+6,396
New +$202K 0.04% 74

Other funds holding PFE

LBMC Investment Advisors's PFE Position: Q2 2026 in Review

LBMC Investment Advisors reduced its Pfizer (PFE) stake by 22% in Q2 2026, selling an estimated $78.5K and leaving 10,922 shares worth $263K. The position accounts for 0.01% of the portfolio, ranked #216.

LBMC Investment Advisors first reported a position in PFE in Q1 2017 and has held it in 33 quarters since. The position peaked at $695K in Q1 2023. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • LBMC Investment Advisors held 10,922 shares of Pfizer worth $263K as of Q2 2026.
  • LBMC Investment Advisors sold 3,000 Pfizer shares in Q2 2026, an estimated $78.5K.
  • Pfizer made up 0.01% of LBMC Investment Advisors's portfolio in Q2 2026, its #216 holding.
  • LBMC Investment Advisors first reported a position in Pfizer in Q1 2017 and has held it in 33 quarters since.
  • LBMC Investment Advisors's Pfizer position peaked at $695K in Q1 2023.
  • 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on LBMC Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.